Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Farooqui(National Heart Lung and Blood Institute), Janet Valdez(National Heart Lung and Blood Institute), Sabrina Martyr(National Institutes of Health), Georg Aue(National Institutes of Health), Nakhle S. Saba(National Heart Lung and Blood Institute), Carsten Utoft Niemann(National Heart Lung and Blood Institute), Sarah E. M. Herman(National Heart Lung and Blood Institute), Xin Tian(National Heart Lung and Blood Institute), Gerald E. Marti(National Heart Lung and Blood Institute), Susan Soto(National Heart Lung and Blood Institute), Thomas E. Hughes(National Heart Lung and Blood Institute), Jade Jones(National Institutes of Health), Andrew Lipsky(National Heart Lung and Blood Institute), Stefania Pittaluga(National Cancer Institute), Maryalice Stetler‐Stevenson(National Institutes of Health), Constance M. Yuan(National Institutes of Health), Yuh Shan Lee(National Heart Lung and Blood Institute), Lone Bredo Pedersen(Rigshospitalet), Christian H. Geisler(Copenhagen University Hospital), Katherine R. Calvo(National Institutes of Health Clinical Center), Diane C. Arthur(National Cancer Institute), Irina Marić(National Institutes of Health Clinical Center), Richard Childs(National Institutes of Health), Neal S. Young(National Institutes of Health), Adrian Wiestner(National Heart Lung and Blood Institute)
Cited by 366Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis